Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers. (PROBATAZO)
Primary Purpose
Enterobacteriaceae Infections
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Piperacillin-tazobactam
Sponsored by
About this trial
This is an interventional treatment trial for Enterobacteriaceae Infections focused on measuring Fecal carriage, Ventilator-associated pneumonia, Piperacillin-tazobactam
Eligibility Criteria
Inclusion Criteria:
- Patient above 18 year-old admitted to intensive care unit
- ESBL-E fecal carriage according to current screening recommendations
- Suspicion of ventilator-associated pneumonia according to ICU society guidelines
Exclusion Criteria:
- Septic shock according to Sepsis-3 classification
- Neutropenia (neutrophils count < 500/mm3)
- Known fecal carriage of Carbapenemase-producing Enterobacteriaceae or multi-drug resistant A. baumanii during the past 6 months.
- Infection with a bacteria resistant to piperacillin-tazobactam during the past 6 months
- Treatment with piperacillin-tazobactam in the 10 previous days
- Proven hypersensitivity to penicillin or tazobactam
- Pregnancy or breastfeeding
- Curatorship or guardianship
- Prisoners
- No health insurance
Sites / Locations
- Centre hospitalier de la Côte BasqueRecruiting
- Hopital PellegrinRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intervention
Arm Description
The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.
Outcomes
Primary Outcome Measures
Mortality in Intensive Care Unit (ICU)
Proportion of patients who died during ICU stay.
Secondary Outcome Measures
Proportion of patients cured of infection on D3 and D7 after inclusion
The proportion of cured patient is defined by the combination of : hemodynamic stability, a stable or improving SOFA score AND a stable or improving Pa02 / FiO2 ratio.
Proportion of patients requiring an escalation of the probabilistic treatment of piperacillin-tazobactam to meropenem.
Therapeutic escalation of piperacillin-tazobactam to meropenem will be performed in patients in whom septic shock according to the Sepsis-3 criteria appears between inclusion and obtaining microbiological documentation and in patients in whom the condition respiratory threatens the short-term life-threatening.
Mortality at day 90
Proportion of patients who died between D0 and D90
Full Information
NCT ID
NCT04276480
First Posted
February 14, 2020
Last Updated
July 18, 2023
Sponsor
University Hospital, Bordeaux
1. Study Identification
Unique Protocol Identification Number
NCT04276480
Brief Title
Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.
Acronym
PROBATAZO
Official Title
Antimicrobial Therapy for Ventilator-associated Pneumonia Among Patients Colonized With Extended-spectrum Beta-lactamase-producing Enterobacteriaceae : Efficacy of a Strategy Using Piperacillin-tazobactam as Empirical Treatment.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 16, 2022 (Actual)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
August 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Antimicrobial resistance is a major threat worldwide and now concerns last-ressource antibiotics such as carbapenems. As the resistance to carbapenems is directly due to their use, their spare has become a public health emergency. Their efficacy in ventilator-associated pneumonia has never been compared to other classes of antibiotics such as piperacillin-tazobactam which can be an alternative to carbapenems.
Detailed Description
The rising antimicrobial resistance has led to more than 33,000 deaths in Europe in 2015. Among them, extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are the most frequent in Europe and carbapenems are recommended as a first line treatment by the guidelines despite the fact they are last-resource agents. Nevertheless, the overuse of carbapenems triggered the emergence of carbapenems-resistant Enterobacteriaceae (CRE). Alternatives to carbapenems are needed to treat ESBL-E infections efficiently without selecting CRE. One strategy described during the last few years is to guide the empirical antimicrobial therapy upon the fecal carriage of ESBL-E. In fact, ESBL-E fecal carriers are more often colonised in the lungs with ESBL-E and have more subsequent ESBL-E infections than non-carriers. However, the positive predictive value of ESBL-E fecal carriage for subsequent ESBL-E is only of 40% despite a negative predictive value of almost 100%. Besides, a before-after cohort study with and without ESBL-E fecal carriage screening exhibited a decrease of carbapenems consumption without any clinical harm. Several studies compared carbapenems vs alternatives after ESBL-E documentation and did not find any clinical harm either but carbapenems were almost always used before documentation. At the best of our knowledge, no study prospectively investigated an alternative to carbapenems for the empirical antimicrobial therapy (before documentation) of ventilator-associated pneumonia despite those encouraging data. This study aims to assess the relevance of piperacillin-tazobactam as the empirical antimicrobial therapy in case of a ventilator-associated pneumonia among ESBL-E fecal carriers. The treatment will be then adapted according to the susceptibility profile. The follow-up of the patients will last until 28 days after their inclusion and until their discharge from intensive care unit if it occurs later. Bacterial susceptibility to the antimicrobial treatment and clinical outcomes will be recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Enterobacteriaceae Infections
Keywords
Fecal carriage, Ventilator-associated pneumonia, Piperacillin-tazobactam
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.
Intervention Type
Drug
Intervention Name(s)
Piperacillin-tazobactam
Intervention Description
At the time of ventilator-associated pneumonia diagnosis, patients will receive an initial 4g loading dose of piperacillin-tazobactam with a continuous maintenance dose of 16g per day the first day of treatment. The dose of the piperacillin-tazobactam administered the following days will be adjusted to the renal function.
The antimicrobial treatment will be adjusted to the narrower-spectrum agent after the antimicrobial susceptibility determination for a total length of treatment of seven days.
Primary Outcome Measure Information:
Title
Mortality in Intensive Care Unit (ICU)
Description
Proportion of patients who died during ICU stay.
Time Frame
at day 28 after inclusion
Secondary Outcome Measure Information:
Title
Proportion of patients cured of infection on D3 and D7 after inclusion
Description
The proportion of cured patient is defined by the combination of : hemodynamic stability, a stable or improving SOFA score AND a stable or improving Pa02 / FiO2 ratio.
Time Frame
at day 7 after inclusion
Title
Proportion of patients requiring an escalation of the probabilistic treatment of piperacillin-tazobactam to meropenem.
Description
Therapeutic escalation of piperacillin-tazobactam to meropenem will be performed in patients in whom septic shock according to the Sepsis-3 criteria appears between inclusion and obtaining microbiological documentation and in patients in whom the condition respiratory threatens the short-term life-threatening.
Time Frame
at day 28 after inclusion
Title
Mortality at day 90
Description
Proportion of patients who died between D0 and D90
Time Frame
at day 90 after inclusion
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient above 18 year-old admitted to intensive care unit
ESBL-E fecal carriage according to current screening recommendations
Suspicion of ventilator-associated pneumonia according to ICU society guidelines
Exclusion Criteria:
Septic shock according to Sepsis-3 classification
Neutropenia (neutrophils count < 500/mm3)
Known fecal carriage of Carbapenemase-producing Enterobacteriaceae or multi-drug resistant A. baumanii during the past 6 months.
Infection with a bacteria resistant to piperacillin-tazobactam during the past 6 months
Treatment with piperacillin-tazobactam in the 10 previous days
Proven hypersensitivity to penicillin or tazobactam
Pregnancy or breastfeeding
Curatorship or guardianship
Prisoners
No health insurance
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maxime POTEAU, Dr
Phone
05 56 79 55 17
Ext
+33
Email
maxime.poteau@chu-borbeaux.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Renaud PREVEL, Dr
Phone
05 56 79 55 17
Ext
+33
Email
renaud.prevel@chu-borbeaux.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laura RICHERT, Dr
Organizational Affiliation
USMR
Official's Role
Study Chair
Facility Information:
Facility Name
Centre hospitalier de la Côte Basque
City
Bayonne
ZIP/Postal Code
64100
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chloé GISBERT-MORA, Dr
Phone
05 59 44 36 12
Ext
+33
Email
cgisbert-mora@ch-cotebasque.fr
Facility Name
Hopital Pellegrin
City
Bordeaux
ZIP/Postal Code
33000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maxime POTEAU, Dr
Phone
05 56 79 55 17
Ext
+33
Email
maxime.poteau@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Renaud PREVEL, Dr
Phone
05 56 79 55 17
Ext
+33
Email
renaud.prevel@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Didier GRUSON, Pr
First Name & Middle Initial & Last Name & Degree
Cédric CARRIE, Dr
First Name & Middle Initial & Last Name & Degree
Noémie SAUVAGE, Dr
12. IPD Sharing Statement
Learn more about this trial
Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.
We'll reach out to this number within 24 hrs